TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02724163
Drug: Busulfan
Normalized name: Busulfan
DrugBank: Busulfan (DB01008)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Alkylsulfonate
Study: NCT00292708
Drug: Cefmetazole (drug)
Normalized name: Cefmetazole
DrugBank: Cefmetazole (DB00274)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT01152996
Drug: Vortioxetine
Normalized name: Vortioxetine
DrugBank: Vortioxetine (DB09068)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Vortioxetine tablets
Study: NCT00816127
Drug: Desmopressin
Normalized name: Desmopressin
DrugBank: Desmopressin (DB00035)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: intranasal desmopressin (300μg)
Study: NCT01241708
Drug: Bortezomib
Normalized name: Bortezomib
DrugBank: Bortezomib (DB00188)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Bortezomib 1.6mg/m2 on day -4 and day -1
Study: NCT00169104
Drug: G-CSF
Normalized name: G-CSF
DrugBank: Filgrastim (DB00099)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 5 mcgm/kg daily Monday through Friday weeks 3-14
Study: NCT00169104
Drug: trastuzumab
Normalized name: trastuzumab
DrugBank: Trastuzumab (DB00072)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 4 mcgm/kg intravenously (IV) over 90 minutes week 1, then 2 mg/kg IV over 30 minutes weeks 2-14
Study: NCT00169104
Drug: vinorelbine
Normalized name: Vinorelbine
DrugBank: Vinorelbine (DB00361)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 25 mg/m2 over 6 minutes IV weekly, weeks 3, 4, 6, 7, 9, 10, 12, 13
Study: NCT00169104
Drug: G-CSF
Normalized name: G-CSF
DrugBank: Filgrastim (DB00099)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 5 mcgm/kg SQ daily for ten days, Monday through Friday of the first two weeks of the study
Study: NCT00576862
Drug: INSULIN GLARGINE
Normalized name: Insulin Glargine
DrugBank: Insulin glargine (DB00047)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: The subjects will continue the treatment with HOE 901 in the same way as they have done in the previous study. Based on the investigator's assessment and the approved SPC in Belgium/Luxembourg, the dosage can be adjusted individually. HOE 901 is to be injected once daily. HOE 901 must not be mixed with any other insulin, including regular human insulin or fast-acting insulin analogues.
Study: NCT00463918
Drug: varenicline
Normalized name: Varenicline
DrugBank: Varenicline (DB01273)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT01178125
Drug: DR-102
Normalized name: Dr. Numb
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT03227731
Drug: Truvada
Normalized name: Truvada
DrugBank: Tenofovir disoproxil (DB00300)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Truvada (Truvada (emtricitabine 200mg/tenofovir disoproxil fumarate 300mg) is in a fixed-dose combination (FDC) tablet formulation and is proven safe for the prevention and treatment of HIV in non-pregnant and non-lactating women.
Study: NCT02956538
Drug: Thalidomide
Normalized name: Thalidomide
DrugBank: Thalidomide (DB01041)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT02956538
Drug: placebo(for thalidomide)
Normalized name: Thalidomide
DrugBank: Thalidomide (DB01041)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: sugar pill manufactured to mimic thalidomide 100mg tablet
Study: NCT00248157
Drug: Octreotide acetate in microspheres
Normalized name: Octreotide Acetate
DrugBank: Octreotide (DB00104)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT01726075
Drug: Brimonidine
Normalized name: Brimonidine
DrugBank: Brimonidine (DB00484)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: One drop per eye twice a day during 24 months
Study: NCT03410992
Drug: Bimekizumab
Normalized name: bimekizumab
DrugBank: Bimekizumab (DB12917)
Approvals — FDA: no, EMA: yes, PMDA: yes
Description: Bimekizumab will be provided at pre-specified time intervals.
Study: NCT03050177
Drug: Gefitinib Tablet 250mg of Hunan Kelun
Normalized name: gefitinib
DrugBank: Gefitinib (DB00317)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Single dose of Gefitinib Tablet 250mg of Hunan Kelun was administered under fed conditions after a 10-hour overnight fast.
Study: NCT01280526
Drug: Romidepsin and CHOP
Normalized name: Romidepsin
DrugBank: Romidepsin (DB06176)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Romidepsin dose administered IV at day 1 and 8 or at day 1 without day 8 in combination with cyclophosphamide, doxorubicin, vincristine and prednisone (CHOP) administered every 3 weeks for 8 cycles in patients with T-cell lymphoma
Study: NCT01028404
Drug: insulin aspart
Normalized name: Insulin Aspart
DrugBank: Insulin aspart (DB01306)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: As an active comparator, one standard dose will be given s.c. (under the skin) at all dose levels.
Study: NCT01028404
Drug: insulin aspart
Normalized name: Insulin Aspart
DrugBank: Insulin aspart (DB01306)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: As an active comparator, one standard dose will be given s.c. (under the skin) at one study visit.
Study: NCT01733121
Drug: NBI-98854
Normalized name: NBI-98782
DrugBank: NBI-98782 (DB16905)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 25 mg capsule
Study: NCT01733121
Drug: NBI-98854
Normalized name: NBI-98782
DrugBank: NBI-98782 (DB16905)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50 mg capsule
Study: NCT02602314
Drug: Imatinib
Normalized name: Imatinib
DrugBank: Imatinib (DB00619)
Approvals — FDA: yes, EMA: yes, PMDA: no
Study: NCT02602314
Drug: Nilotinib
Normalized name: Nilotinib
DrugBank: Nilotinib (DB04868)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT02533934
Drug: Harvoni
Normalized name: Harvoni
DrugBank: Sofosbuvir (DB08934)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Treatment of Hepatitis C with sofosbuvir based HCC therapy
Study: NCT00905424
Drug: Antidepressant + SPD489 (lisdexamfetamine dimesylate)
Normalized name: Lisdexamfetamine Dimesylate
DrugBank: Lisdexamfetamine (DB01255)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Escitalopram oxalate (antidepressant) 20 mg/day oral + 20, 30, or 50 mg SPD489 oral once daily for 6 weeks
Study: NCT03307941
Drug: Monalizumab
Normalized name: Monalizumab
DrugBank: Monalizumab (DB12824)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Monalizumab (IPH2201) is given at the recommended dose of 10 mg/kg, intravenously (infusion during 60 minutes) every two weeks
Study: NCT03307941
Drug: Oxaliplatin
Normalized name: Oxaliplatin
DrugBank: Oxaliplatin (DB00526)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: A total of 4 cycles of FOLFOX is administrated every 2 weeks with one cycle 15 days prior to the radiotherapy and 3 cycles during the radiotherapy whatever the level
Study: NCT03307941
Drug: 5-Fluorouracil
Normalized name: 5-fluorouracil
DrugBank: Fluorouracil (DB00544)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: A total of 4 cycles of FOLFOX is administrated every 2 weeks with one cycle 15 days prior to the radiotherapy and 3 cycles during the radiotherapy whatever the level
Study: NCT01585246
Drug: Saw Palmetto
Normalized name: Saw palmetto
DrugBank: Saw palmetto (DB14360)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 of 3 doses of Saw Palmetto (320, 640, 960mg/day)
Study: NCT01585246
Drug: soybean oil soft gel
Normalized name: Soybean Oil
DrugBank: Soybean oil (DB09422)
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo (soybean oil soft gel)
Study: NCT02420262
Drug: insulin degludec/liraglutide
Normalized name: INSULIN DEGLUDEC/LIRAGLUTIDE
DrugBank: Liraglutide (DB06655)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Once daily injected s.c./subcutaneously (under the skin) in combination with metformin.
Study: NCT02420262
Drug: insulin glargine
Normalized name: Insulin Glargine
DrugBank: Insulin glargine (DB00047)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Once daily injected s.c./subcutaneously (under the skin) in combination with metformin.
Study: NCT02420262
Drug: insulin aspart
Normalized name: Insulin Aspart
DrugBank: Insulin aspart (DB01306)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Injected s.c./subcutaneously (under the skin) before each main meal.
Study: NCT00624000
Drug: IV tpa (Alteplase) vs IA tpa (Alteplase)
Normalized name: tPA
DrugBank: Alteplase (DB00009)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Alteplase was administered Either IA or IV x 1
Study: NCT04229706
Drug: High dose Xiang Ju Ru Pi Ning capsule
Normalized name: high-density polyethylene
DrugBank: Poly(lactic acid) (DB15037)
Approvals — FDA: no, EMA: no, PMDA: no
Description: xingjurupining capsule,8 capsule,tid,3 months.
Study: NCT04229706
Drug: Low dose Xiang Ju Ru Pi Ning capsule
Normalized name: low-density polyethylene
DrugBank: Poly(lactic acid) (DB15037)
Approvals — FDA: no, EMA: no, PMDA: no
Description: xiangjurupining capsule,4 capsules , and xiangjurupining capsule placebo,4 capsules,tid,3 months.
Study: NCT03891433
Drug: Meropenem
Normalized name: Meropenem
DrugBank: Meropenem (DB00760)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Carbapenems group intervention.
Study: NCT03891433
Drug: Ertapenem 1000 MG
Normalized name: ertapenem 1000 MG
DrugBank: Ertapenem (DB00303)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Carbapenems group intervention.
Study: NCT03891433
Drug: Piperacillin, Tazobactam 4-0.5G Solution for Injection
DrugBank: Piperacillin (DB00319)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Piperacillin/Tazobactam group intervention.
Study: NCT01852513
Drug: QNASL
Normalized name: Qnasl
DrugBank: Beclomethasone dipropionate (DB00394)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00371813
Drug: Varenicline tartrate
Normalized name: Varenicline tartrate
DrugBank: Varenicline (DB01273)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT02485613
Drug: bortezominb and dexamethasone
Normalized name: Dexamethasone
DrugBank: Dexamethasone (DB01234)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: The initial BD regimen included bortezomib (1.3 mg/m2 i.v.) and dexamethasone (40 mg i.v.) twice weekly for 2 weeks (days 1, 4, 8, and 11), which was followed by a 10-day rest period (days 12-21). The dose of bortezomib and dexamethasone can be adjusted according to the patients' condition.
Study: NCT02215616
Drug: Laquinimod
Normalized name: laquinimod
DrugBank: Laquinimod (DB06685)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Laquinimod capsules will be administered as per the dose and schedule specified in the respective arms.
Study: NCT00324740
Drug: vorinostat
Normalized name: Vorinostat
DrugBank: Vorinostat (DB02546)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Given orally
Study: NCT00324740
Drug: isotretinoin
Normalized name: Isotretinoin
DrugBank: Isotretinoin (DB00982)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Given orally
Study: NCT00124813
Drug: thalidomide
Normalized name: Thalidomide
DrugBank: Thalidomide (DB01041)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00124813
Drug: idarubicin
Normalized name: Idarubicin
DrugBank: Idarubicin (DB01177)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: oral idarubicin
Study: NCT02539719
Drug: SC-003 in combination with ABBV-181
Normalized name: miconazole
DrugBank: Miconazole (DB01110)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT01594346
Drug: Alpha-Tocopherol
Normalized name: Alpha-tocopherol
DrugBank: alpha-Tocopherol succinate (DB14001)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1,000 International Units, two times a day for 36 months
Study: NCT01594346
Drug: Sugar Pill
Normalized name: Invert Sugar
DrugBank: Invert sugar (DB09344)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00639262
Drug: Sorafenib
Normalized name: Sorafenib
DrugBank: Sorafenib (DB00398)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sorafenib 200mg twice daily during XRT and 30 days after. (Sorafenib will be escalated for both cohorts to determine maximum tolerated dose)
Study: NCT00639262
Drug: Temozolomide
Normalized name: Temozolomide
DrugBank: Temozolomide (DB00853)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: For Cohort 2 - Gliomas only.
Study: NCT01818986
Drug: Sipuleucel-T
Normalized name: Sipuleucel-T
DrugBank: Sipuleucel-T (DB06688)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03582917
Drug: Alphacalcidol
Normalized name: alfacalcidol
DrugBank: Alfacalcidol (DB01436)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alphacalcidol 0,5mg tablet
Study: NCT00278863
Drug: S-1
Normalized name: LIS-1
DrugBank: Tegafur (DB09256)
Approvals — FDA: no, EMA: yes, PMDA: no
Study: NCT00596050
Drug: ketamine and midazolam
DrugBank: Midazolam (DB00683)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: ketamine 1 mg/kg/dose, midazolam 0.05 mg/kg/dose max 2 mg
Study: NCT00596050
Drug: etomidate, fentanyl, and lidocaine
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: etomidate 0.2 mg/kg/dose, fentanyl 1 microgram/kg/dose, lidocaine 0.5 mg/kg/dose
Study: NCT01566422
Drug: Vancomycin powder
Normalized name: Vancomycin
DrugBank: Vancomycin (DB00512)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: patients randomized to this group will receive vancomycin powder in the surgical incision after posterior spinal fusion.
Study: NCT04435522
Drug: Maraviroc
Normalized name: Maraviroc
DrugBank: Maraviroc (DB04835)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Maraviroc will be administered for seven days. Biomarkers of disease will be checked at time of enrollment, during and at the conclusion of therapy. The cytokine panel will consist of CCL5, IL-6, and Chitinase 3-like 1(Chi3l1).
Study: NCT02074878
Drug: Crixotinib 200 mg and Sunitinib Cohort 1
DrugBank: Sunitinib (DB01268)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Crizotinib 200 mg, twice daily with Sunitinib 25.0 mg once a day
Study: NCT02074878
Drug: Crixotinib 250 mg and Sunitinib Cohort 2
DrugBank: Sunitinib (DB01268)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Crizotinib 250 mg, twice daily with Sunitinib 25.0 mg once a day
Study: NCT02074878
Drug: Crizotinib & Sunitinib 37.5 mg Cohort 3
DrugBank: Sunitinib (DB01268)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Crizotinib 250 mg, twice daily with Sunitinib 37.5 mg once a day
Study: NCT01874522
Drug: TAS-102 tablets
Normalized name: Ta
DrugBank: TAS-102 (DB08937)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Crossover bioavailability part: 60 mg/dose, orally, up to 2 single doses separated by 1-week washout.~Extension part: 35 mg/m2/dose, orally, twice daily on days 1-5 and 8-12 of each 28-day cycle. Number of cycles: until at least one of the discontinuation criteria is met.
Study: NCT01874522
Drug: TAS-102 oral solution
Normalized name: Ta
DrugBank: TAS-102 (DB08937)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 60 mg/dose, orally, up to 2 single doses separated by 1-week washout
Study: NCT03925402
Drug: Ertapenem
Normalized name: Ertapenem
DrugBank: Ertapenem (DB00303)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Ertapenem injection
Study: NCT03925402
Drug: Carbapenems
Normalized name: Carbapenems
DrugBank: Carbapenem (DB18912)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Other carbapenems injection
Study: NCT01204086
Drug: Venlafaxine
Normalized name: Venlafaxine
DrugBank: Venlafaxine (DB00285)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: The initial dose of venlafaxine was 37.5 mg once daily for 4 days titrated to 75 mg once daily, which could be increased by 75 mg in divided doses to a maximal daily dose of 225 mg.
Study: NCT01818973
Drug: Xeloda
Normalized name: Xeloda
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: po, 1000mg/m2/12h daily, day 1 in the afternoon until day 15 in the morning, 8 cycles
Study: NCT01818973
Drug: Oxaliplatin
Normalized name: Oxaliplatin
DrugBank: Oxaliplatin (DB00526)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: iv, 130mg/m2, day 1, 1 cycle during neoadjuvant chemotherapy and 3 cycles in adjuvant chemotherapy 100mg/m2, day 1, 2 cycles during concurrent chemoradiotherapy
Study: NCT01818973
Drug: Bevacizumab
Normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: iv, 7.5 mg/kg, day 1, 3 cycles during neoadjuvant chemotherapy and concurrent chemoradiotherapy
Study: NCT03320174
Drug: Tafenoquine
Normalized name: tafenoquine
DrugBank: Tafenoquine (DB06608)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tafenoquine 200mg
Study: NCT03135509
Drug: CC-220
Normalized name: CC
DrugBank: Cholecalciferol (DB00169)
Approvals — FDA: no, EMA: no, PMDA: no
Description: CC-220 gelatin capsules
Study: NCT03789097
Drug: Pembrolizumab
Normalized name: Pembrolizumab
DrugBank: Pembrolizumab (DB09037)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 200 mg administered as an IV infusion over 30 minutes Q3W
Study: NCT03789097
Drug: Poly ICLC
Normalized name: Poly iclc
DrugBank: Hiltonol (DB17293)
Approvals — FDA: no, EMA: no, PMDA: no
Description: an immune cell activating factor. vials containing 1 ml of 2 mg/mL
Study: NCT03162185
Drug: Escitalopram
Normalized name: Escitalopram
DrugBank: Escitalopram (DB01175)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Experimental group participants (n = 30) will receive 20 mg of Escitalopram for 7 days.
Study: NCT02686164
Drug: Lenvatinib
Normalized name: Lenvatinib
DrugBank: Lenvatinib (DB09078)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Lenvatinib 24 mg (as one 4 mg and two 10 mg capsules) will be administered orally once daily with 240 mL (8 fluid oz) of water each morning, starting on Cycle 1 Day 1, in 28-day cycles.
Study: NCT02686164
Drug: Midazolam
Normalized name: Midazolam
DrugBank: Midazolam (DB00683)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Midazolam syrup 4 mg will be administered orally after an overnight fast on Cycle 1 Day -3 and concurrently with lenvatinib on Day 1 and Day 14 of Cycle 1. Participants will have to remain fasting for 2 hours after each dose of midazolam.
Study: NCT00805129
Drug: Everolimus
Normalized name: Everolimus
DrugBank: Everolimus (DB01590)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Everolimus (RAD001) is a novel oral derivative of rapamycin. Everolimus will be administered orally as a once-daily dose of 10 mg (two 5 mg tablets) continuously from study day 1 until progression of disease or unacceptable toxicity. Patients will be instructed to take Everolimus in the morning, at the same time each day. Everolimus should be taken by the patient in a fasting state or with no more than a light fat-free meal.
Study: NCT00563615
Drug: Tegaserod
Normalized name: Tegaserod
DrugBank: Tegaserod (DB01079)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT01067534
Drug: Salbutamol
Normalized name: Salbutamol
DrugBank: Albuterol (DB01001)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Inhaler salbutamol 0,1 mg/dose - 4 doses=0,4 mg
Study: NCT00647972
Drug: Olanzapine Tablets 20 mg
Normalized name: olanzapine Oral Tablet
DrugBank: Olanzapine (DB00334)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 20mg, single dose fasting
Study: NCT00280592
Drug: Cranberry
Normalized name: Cranberry
DrugBank: Cranberry (DB10631)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dry essence of cranberry presented as 18 mg of proanthocyanidines sachets of powdered cranberry. Cranberry juice is administered twice a day (in the morning and in the evening).
Study: NCT01689441
Drug: Calcitriol
Normalized name: Calcitriol
DrugBank: Calcitriol (DB00136)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT01853293
Drug: Kudzu extract
Normalized name: Aminobenzoic Acid/Black Cohosh Extract/Boron/Dong Quai Extract/Ginseng Extract, Korean/Hesperidin/Kudzu Extract/Licorice Extract/Resveratrol/Wild Yam Extract 50 MG-25 MG-25 MCG-25 MG-100 MG-50 MG-25 MG-37.5 MG-0.5 MG-25 MG Oral Capsule
DrugBank: Ginseng (DB01404)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02260206
Drug: Colchicine
Normalized name: Colchicine
DrugBank: Colchicine (DB01394)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Impact of Colchicine therapy on arrhythmia Recurrence after Acute Pericardial Effusion following Catheter Ablation of Atrial Fibrillation
Study: NCT03633591
Drug: Tolcapone
Normalized name: Tolcapone
DrugBank: Tolcapone (DB00323)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Multiple doses of tolcapone tablets in the fasted state
Study: NCT03633591
Drug: Tolcapone Modified Release Prototype
Normalized name: Tolcapone
DrugBank: Tolcapone (DB00323)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: A single dose of tolcapone modified release prototype in the fasted state
Study: NCT06720233
Drug: SAL-0951 tablets
Normalized name: salicylate
DrugBank: Bismuth subsalicylate (DB01294)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: initial phase：4mg QD subsequent phase：1mg～8mg QD，adjust the dose based on hemoglobin concentration level every 4 weeks
Study: NCT01388153
Drug: Acarbose (Glucobay ODT, BAYG5421)
Normalized name: Acarbose
DrugBank: Acarbose (DB00284)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Day 1: oral sucrose load (75 g sucrose dissolved in 225 mL water) without Glucobay ODT; Day 2: oral sucrose load plus Glucobay ODT taken without water
Study: NCT01388153
Drug: Acarbose (Glucobay ODT, BAYG5421)
Normalized name: Acarbose
DrugBank: Acarbose (DB00284)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Day 1: oral sucrose load (75 g sucrose dissolved in 225 mL water) without Glucobay ODT; Day 2: oral sucrose load plus Glucobay ODT taken with water
Study: NCT01388153
Drug: Acarbose (Glucobay, BAYG5421)
Normalized name: Acarbose
DrugBank: Acarbose (DB00284)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Day 1: oral sucrose load (75 g sucrose dissolved in 225 mL water) without Glucobay standard tablet; Day 2: oral sucrose load plus Glucobay standard tablet taken with water
Study: NCT02740959
Drug: Astragalus Polysaccharides 500 mg
Normalized name: Astragalus polysaccharides
DrugBank: Astragalus mongholicus root polysaccharides (DB17721)
Approvals — FDA: no, EMA: no, PMDA: no
Description: PG2 Injection 500 mg PG2 (500 mg in 500 ml saline), t.i.w. via i.v. infusion for 2.5-3.5 hours over 2 treatment cycles (8 weeks)
Study: NCT02740959
Drug: Astragalus Polysaccharides 250 mg
Normalized name: Astragalus polysaccharides
DrugBank: Astragalus mongholicus root polysaccharides (DB17721)
Approvals — FDA: no, EMA: no, PMDA: no
Description: PG2 Injection 250 mg PG2 (250 mg in 500 ml saline), t.i.w. via i.v. infusion for 2.5-3.5 hours over 2 treatment cycles (8 weeks)
Study: NCT03633591
Drug: Tolcapone Divided Dose
Normalized name: Tolcapone
DrugBank: Tolcapone (DB00323)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tolcapone (suspension) in equal divided doses in the fasted state
Study: NCT03633591
Drug: Tolcapone Modified Release Prototype
Normalized name: Tolcapone
DrugBank: Tolcapone (DB00323)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: A single dose of tolcapone modified release prototype (optionally two doses or fed state of prior MR prototype)
Study: NCT04653389
Drug: Sintilimab Injection
Normalized name: Sintilimab
DrugBank: Sintilimab (DB15765)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sintilimab Injection is used as neoadjuvant therapy and adjuvant therapy.
Study: NCT03199950
Drug: Haloperidol
Normalized name: Haloperidol
DrugBank: Haloperidol (DB00502)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Haloperidol 2dd1mg (08.00am - 10.00pm)
Study: NCT03113110
Drug: Empagliflozin 10 mg
Normalized name: empagliflozin 10 MG
DrugBank: Empagliflozin (DB09038)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: PTDM patients on previous antidiabetic treatment (\<40 IU insulin (in some cases plus oral antidiabetics)) receive Empagliflozin, ideally as monotherapy
Study: NCT04118647
Drug: Wu-Chu-Yu tang
Normalized name: Yu Jin
DrugBank: Turmeric (DB14276)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Wu-Chu-Yu tang at a rate of 3.0 g three times per day for 28 days.